The Regensburg-based digital health startup brainjo has closed a €2 million seed funding round. Using virtual reality (VR) as a prescribable therapeutic supplement with high adherence rates, the company aims to address the underservice of children with ADHD caused by a shortage of therapy slots and excessively long waiting lists. The round is led by High-Tech Gründerfonds (HTGF); other investors include strategic partners and business angels, such as Andreas Weinhut from Regensburg and better ventures from Munich.
brainjo develops digital health applications (DiGA) that are prescribed by therapists or doctors and reimbursed by health insurance. The approach: not to replace traditional psychotherapy, but to fill the gaps left by the system. Patients thus gain access to an immersive, personalized, and scalable form of therapy, complementing existing treatment options and available directly from home.
The seed funding marks the start of the startup’s next phase: With the fresh capital, brainjo will finance the approval of its first VR-DiGA—a digital therapy application specifically for children with ADHD, developed in collaboration with the MEDICE Health Family. Market approval is planned for 2028.
“We’ve been in contact with the agile and dynamic team at brainjo for quite some time now. In particular, the strategic fit of VR therapy is an ideal complement to our range of therapeutic services,” explains Dr. Felix Lambrecht of MEDICE – The Health Family.
“We were convinced from the very beginning—of the team, the technology, and the market. Digital therapies in psychotherapy are still in their infancy, but the potential is enormous. What sets brainjo apart from purely software-based solutions is the depth of immersion provided by virtual reality—a clinically relevant approach that we will substantiate with study data to increase adherence,” says Dr. Jörg Traub, Principal at HTGF.
Markus Wensauer, co-founder and CEO of brainjo, is pleased with the funding: “With a strong network of business angels, the MEDICE Health Family as a strategic partner, and HTGF as a leading European seed investor, we are perfectly positioned to bring our solutions into clinical practice and establish multimodal therapy options for patients.”